SRT3 N Stock Overview
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Sartorius Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €7,920.35 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 0.69 |
| 1 Month Change | 0% |
| 3 Month Change | 1.63% |
| 1 Year Change | 12.15% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -2.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| SRT3 N | MX Life Sciences | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 12.1% | 0% | 0% |
Return vs Industry: SRT3 N exceeded the MX Life Sciences industry which returned -14.6% over the past year.
Return vs Market: SRT3 N exceeded the MX Market which returned 3.7% over the past year.
Price Volatility
| SRT3 N volatility | |
|---|---|
| SRT3 N Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: SRT3 N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SRT3 N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1870 | 15,547 | Joachim Kreuzburg | www.sartorius.com |
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. It offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, as well as software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and membrane filters, glass and quartz microfibre filters, syringeless and in-line filters, lab chromatography, and filters and blotting papers. The company also provides live-cell analysis systems, reagents and consumables, and live-cell imaging and analysis software; equipment manufacturer membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and detection systems, sensor chips and consumables, systems, biosensors and kits, compliance tools, and systems software.
Sartorius Aktiengesellschaft Fundamentals Summary
| SRT3 N fundamental statistics | |
|---|---|
| Market cap | Mex$388.72b |
| Earnings (TTM) | Mex$10.51b |
| Revenue (TTM) | Mex$75.35b |
40.8x
P/E Ratio5.7x
P/S RatioIs SRT3 N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRT3 N income statement (TTM) | |
|---|---|
| Revenue | €4.05b |
| Cost of Revenue | €1.93b |
| Gross Profit | €2.13b |
| Other Expenses | €1.56b |
| Earnings | €565.50m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Jul 21, 2023
| Earnings per share (EPS) | 8.27 |
| Gross Margin | 52.49% |
| Net Profit Margin | 13.95% |
| Debt/Equity Ratio | 96.2% |
How did SRT3 N perform over the long term?
See historical performance and comparison